This Kohl's Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday
This Kohl's Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday
这位Kohl's分析师不再看好;以下是周一的前五大评级下调。
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
华尔街顶级分析师改变了对这些顶级公司的展望。如需查看包括升级和降级在内的所有分析师评级变化的完整视图,请参阅我们的分析师评级页面。
- Morgan Stanley analyst Patrick Wood downgraded the rating for Glaukos Corporation (NYSE:GKOS) from Equal-Weight to Underweight and announced a $120 price target. Glaukos shares closed at $143.65 on Friday. See how other analysts view this stock.
- TD Cowen analyst Andrew Kligerman downgraded Markel Group Inc. (NYSE:MKL) from Buy to Hold and lowered the price target from $1,986 to $1,836. Markel Group shares closed at $1,782.92 on Friday. See how other analysts view this stock.
- Guggenheim analyst Robert Drbul downgraded the rating for Kohl's Corporation (NYSE:KSS) from Buy to Neutral. Kohl's shares closed at $14.97 on Friday. See how other analysts view this stock.
- Goldman Sachs analyst Will Nance downgraded Toast, Inc (NYSE:TOST) from Buy to Neutral but raised the price target from $34 to $45. Toast shares closed at $43.54 on Friday. See how other analysts view this stock.
- Chardan Capital analyst Daniil Gataulin downgraded Outlook Therapeutics, Inc. (NASDAQ:OTLK) from Buy to Neutral. Outlook Therapeutics shares closed at $2.05 on Friday. See how other analysts view this stock.
- 摩根士丹利分析师Patrick Wood将Glaukos公司(纽交所:GKOS)的评级从等权降级为低保证金,并宣布目标价为120美元。 Glaukos股价周五收于143.65美元。看看其他分析师如何看待这只股票。
- TD Cowen分析师Andrew Kligerman将Markel Group公司(纽交所:MKL)的评级从买入调整为持有,将目标价从1,986美元降至1,836美元。 Markel Group股价周五收于1,782.92美元。看看其他分析师如何看待这只股票。
- 古根海姆分析师Robert Drbul将Kohl's公司(纽交所:KSS)的评级从买入调降为中立。 Kohl's股价周五收于14.97美元。看看其他分析师如何看待这只股票。
- 高盛分析师Will Nance将Toast, Inc(纽交所:TOST)的评级从买入调整为中立,但将目标价从34美元提高至45美元。 Toast股价周五收于43.54美元。看看其他分析师如何看待这只股票。
- Chardan Capital分析师Daniil Gataulin将Outlook Therapeutics, Inc(纳斯达克:OTLK)的评级从买入调降为中立。 Outlook Therapeutics股价周五收于2.05美元。看看其他分析师如何看待这只股票。
Considering buying KSS stock? Here's what analysts think:
考虑购买KSS股票?以下是分析师的看法:
Read This Next:
Read This Next:
- How To Earn $500 A Month From Marvell Technology Stock Ahead Of Q3 Earnings
- 如何在迈威尔科技股票的Q3盈利发布之前每个月赚取500美元
译文内容由第三方软件翻译。
以上内容仅用作资讯或教育之目的,不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。